Meet Dr. Geoffrey Allan, former CEO of Insmed, a biopharmaceutical company known for its innovative approaches in medicine. Dr. Allan was at the helm from 2005 until 2009, leading the company through major transitions, including a significant sale of assets...

Meet Dr. Geoffrey Allan, former CEO of Insmed, a biopharmaceutical company known for its innovative approaches in medicine. Dr. Allan was at the helm from 2005 until 2009, leading the company through major transitions, including a significant sale of assets to Merck. During his tenure, he played a vital role in clinical trials and strategic partnerships that aimed to improve the company’s market position. Despite stepping down for health reasons in 2009, his impact was felt in the way Insmed operated and developed products. Interestingly, Dr. Allan's compensation package was tied closely to company performance, with bonuses linked directly to achieving corporate goals. He held a substantial stake in the company, owning over 2 million shares before his departure. Dr. Allan truly exemplified a hands-on leader with a strong focus on aligning his interests with those of the shareholders. His journey reflects both the challenges and rewards of leading a biotech firm in a competitive landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Insmed CEOs

I

Dr. Geoffrey Allan

Ex-CEO of Insmed

Education

N/A

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

June 19, 1958 - 67 years ago

CEO of Insmed for

3 years 10 months (Aug 2005 - Jun 2009)

Previous Experience

N/A

Rivals

Competitors/colleagues of Dr. Geoffrey Allan

Holdings

See how much did Dr. Geoffrey Allan make over time.

Dr. Geoffrey Allan held a significant position at Insmed, boasting over 2 million shares during his tenure as CEO. His wealth was closely linked to Insmed's performance and he held a substantial stake, making him a major stakeholder. At his...

Dr. Geoffrey Allan held a significant position at Insmed, boasting over 2 million shares during his tenure as CEO. His wealth was closely linked to Insmed's performance and he held a substantial stake, making him a major stakeholder. At his peak in the company, his holdings represented about 1.7% of overall shares, reflecting his commitment and confidence in Insmed's future. After departures, stock fluctuations had varied impacts on his net worth, but he consistently demonstrated that his interests were aligned with the company's success. His wealth from holdings fluctuated, peaking during his leadership era and transitioning as he moved away from the company.

Loading...

Insider Trading

See recent insider trades of Dr. Geoffrey Allan.

No insider trades found for this CEO.

Compensation History

See how much did Dr. Geoffrey Allan make over time.

Throughout his presidency at Insmed, Dr. Geoffrey Allan’s compensation varied as the company navigated through different fiscal periods. In 2008, he earned a total compensation of around $1.26 million, driven by a base salary of $450,000 and the maximum discretionary cash bonus of $225,000 based on his leadership during the successful sale of follow-on biologics assets to Merck. However, in 2009, after only part of the fiscal year at the helm, his total compensation was about $909,215 due to his resignation amid health issues. His compensation was intricately linked to his performance as CEO, with heavy emphasis on stock options and performance metrics. His focus was not just on salary but on creating long-term value for shareholders.

Year

2009

Total Compensation

$1.61M

Salary

$209.64K

Board Justification

The company's compensation philosophy aims to attract, retain, and motivate highly qualified executives while aligning compensation with shareholder interests and performance metrics.

Bonus

$0.00

Board Justification

No bonus was awarded for fiscal 2009 as he was only employed for a partial year before resigning due to health reasons.

Other

$699.58K

Board Justification

Includes a lump sum severance payment of $675,000 and other benefits related to the personal use of a vehicle provided by the company.

Restricted Stock

$699.58K(247.58K restricted stock)

Board Justification

The 2008 restricted stock and restricted stock unit grants to Dr. Allan vested on March 31, 2009 as a result of the Merck transaction prior to his resignation.

Performance Metrics

The performance metrics for 2009 included the successful conclusion of the sale of Follow on Biologics assets to Merck, completion of clinical trials, and strategic business reviews.

Other Insmed CEOs

Here are other CEOs of Insmed

Timothy Whitten

Ex-CEO of Insmed

December 2010 - September 2012